ImpediMed Reports 46% Annual Revenue Growth and Key Business Milestones Amid Pandemic Challenges

ACB News《ACB Financial Online》August 25 Report: Medical device company ImpediMed (ASX: IPD) released its full-year financial results on Wednesday. The report indicated that despite the ongoing adverse impact of the COVID-19 pandemic, the company's full-year revenue still achieved a 46% increase, reaching AUD 8.4 million.

ImpediMed continued to advance the commercialization of its core product, the SOZO digital health platform, during the fiscal year, achieving total revenue of AUD 7.6 million, a 64% year-on-year increase. Currently, there are 770 SOZO devices in the market, an increase of 205 units compared to the previous year. Within the SOZO business segment, Software-as-a-Service (SaaS) revenue reached AUD 6 million, up 77% year-on-year, with a gross margin exceeding 90%; clinical business revenue totaled AUD 1.9 million, with the largest contract secured from AstraZeneca for two Phase II clinical trials.

ImpediMed is a medical software technology company that utilizes bioimpedance spectroscopy (BIS) to assess, analyze, and manage fluid status and tissue composition. The company currently focuses on three key areas: oncology, heart failure, and renal failure.

Richard Carreon, Chief Executive Officer of ImpediMed, stated that the company achieved several milestone developments over the past year, the most significant of which was the completion of the PREVENT trial. This randomized controlled trial focused on patients at risk of cancer-related lymphedema, aiming to detect subclinical extracellular fluid accumulation using bioimpedance spectroscopy (BIS) and to determine whether early intervention could effectively reduce the rate of lymphedema progression. The trial results are currently undergoing peer review, which Richard described as a groundbreaking and landmark study.

Another significant achievement for ImpediMed is the demonstration that the company’s SOZO HF-Dex™ device, when utilized as an assessment tool at discharge for heart failure patients, effectively aids in identifying those at high risk of hospital readmission. During the fiscal year, the device secured its first order for heart failure monitoring and received U.S. Food and Drug Administration (FDA) approval in April. Its clinical utility has been validated by leading organizations, including the American College of Cardiology.

In the next phase, the company will continue to leverage pilot projects to expand commercial sales of the SOZO platform for heart failure monitoring, and continue to collaborate with the FDA to obtain approval to remove the contraindication for the SOZO platform in patients with implantable pacemaker and cardioverter-defibrillator devices.

Regarding renal disease, the SOZO platform received Breakthrough Device Designation from the U.S. FDA this Monday for a proposed indication in patients with kidney disease. The platform is currently being utilized in two Phase II trials sponsored by AstraZeneca, and ImpediMed will leverage the data from these trials to develop relevant clinical, regulatory, and commercial strategies for the renal failure market.

【Editor's Tip:】When reading on a mobile device, tap the logo in the top-left corner of the article page to return to the homepage. Wishing our readers good health and happiness every day! May your work and investments proceed smoothly.

Disclaimer: This article is a financial commentary and does not constitute any investment advice. Please consult a professional before making any trading or investment decisions.

(Copyright Notice: ACB News "Australia-China Finance Online" reserves all copyright for articles marked as original. Please cite the source for any reproduction in any form.)